The American biotechnology company Moderna will begin clinical trials of a new type of coronavirus vaccine on July 27, CNBC reported, citing a US government database.
About 30 thousand volunteers will participate in the tests. Everyone will receive a dose of a potential vaccine of 0.1 milligrams, and the injection will be repeated in 29 days. Some participants will be vaccinated with a placebo drug.
The company’s vaccine project is supported by the US Federal government, which has allocated almost $ 500 million and selected it as one of the first to start large-scale human trials. A week ago, Reuters reported that there were tensions between the company and government scientists.
Three sources familiar with the vaccine project told the Agency that Moderna, which has not yet produced an approved vaccine and has not conducted major trials, quarreled with government scientists, did not send test reports in time, and rejected expert advice on conducting the study. This led to a delay in the vaccine trial.